KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Novartis Ag (NVS) EBITDA (2016 - 2025)

Novartis Ag's EBITDA history spans 14 years, with the latest figure at $4.9 billion for Q2 2025.

  • On a quarterly basis, EBITDA rose 21.18% to $4.9 billion in Q2 2025 year-over-year; TTM through Jun 2025 was $21.7 billion, a 72.62% increase, with the full-year FY2025 number at $17.6 billion, up 21.31% from a year prior.
  • EBITDA hit $4.9 billion in Q2 2025 for Novartis Ag, down from $7.4 billion in the prior quarter.
  • Over the last five years, EBITDA for NVS hit a ceiling of $7.4 billion in Q4 2024 and a floor of $273.0 million in Q4 2022.
  • Historically, EBITDA has averaged $2.7 billion across 5 years, with a median of $1.6 billion in 2021.
  • The widest YoY moves for EBITDA: up 1887.18% in 2023, down 40.1% in 2023.
  • Tracing NVS's EBITDA over 5 years: stood at $386.0 million in 2021, then fell by 29.27% to $273.0 million in 2022, then soared by 1887.18% to $5.4 billion in 2023, then surged by 36.17% to $7.4 billion in 2024, then tumbled by 34.15% to $4.9 billion in 2025.
  • Business Quant data shows EBITDA for NVS at $4.9 billion in Q2 2025, $7.4 billion in Q4 2024, and $4.0 billion in Q2 2024.